BACKGROUND: P-selectin antagonism decreases thrombosis and inflammation in animal models of venous thrombosis (VT) prophylaxis. This study defines results using a P-selectin receptor antagonist for VT treatment. METHODS: Eight juvenile baboons underwent 6 h of iliofemoral venous stasis to produce an occlusive VT. Two days later, animals were treated for 14 days with rPSGL-Ig, 4 mg/kg (n3), LMWH (n2) or saline (n3) and treatment continued weekly (rPSGL-Ig) or daily (LMWH, saline). The animals were examined and sacrificed 14 days after treatment initiation (n4) or on day 90 (n4). RESULTS: Percent spontaneous vein reopening revealed a significant increase (p <0.05) in the proximal iliac vein in rPSGL-Ig and LMWH animals compared to controls (62%, 70% vs 8%), without differences in inflammation. No anticoagulation, thrombocytopenia, or wound complications were found in rPSGL-Ig animals. At 90 days, recanalization with iliac vein valve competence was found in treated animals. CONCLUSIONS: rPSGL-Ig successfully treated established VT without anticoagulation.
BACKGROUND: P-selectin antagonism decreases thrombosis and inflammation in animal models of venous thrombosis (VT) prophylaxis. This study defines results using a P-selectin receptor antagonist for VT treatment. METHODS: Eight juvenile baboons underwent 6 h of iliofemoral venous stasis to produce an occlusive VT. Two days later, animals were treated for 14 days with rPSGL-Ig, 4 mg/kg (n3), LMWH (n2) or saline (n3) and treatment continued weekly (rPSGL-Ig) or daily (LMWH, saline). The animals were examined and sacrificed 14 days after treatment initiation (n4) or on day 90 (n4). RESULTS: Percent spontaneous vein reopening revealed a significant increase (p <0.05) in the proximal iliac vein in rPSGL-Ig and LMWH animals compared to controls (62%, 70% vs 8%), without differences in inflammation. No anticoagulation, thrombocytopenia, or wound complications were found in rPSGL-Ig animals. At 90 days, recanalization with iliac vein valve competence was found in treated animals. CONCLUSIONS: rPSGL-Ig successfully treated established VT without anticoagulation.
Authors: Allan K Metz; Jose A Diaz; Andrea T Obi; Thomas W Wakefield; Daniel D Myers; Peter K Henke Journal: Methodist Debakey Cardiovasc J Date: 2018 Jul-Sep
Authors: Andrea T Obi; Elizabeth Andraska; Yogendra Kanthi; Chase W Kessinger; Megan Elfline; Cathy Luke; Teruna J Siahaan; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke Journal: Thromb Haemost Date: 2016-12-15 Impact factor: 5.249
Authors: Jose A Diaz; Shirley K Wrobleski; Christine M Alvarado; Angela E Hawley; Nichole K Doornbos; Patrick A Lester; Suzan E Lowe; Joy E Gabriel; Karen J Roelofs; Peter K Henke; Robert G Schaub; Thomas W Wakefield; Daniel D Myers Journal: Arterioscler Thromb Vasc Biol Date: 2015-02-05 Impact factor: 8.311
Authors: Eduardo Ramacciotti; Daniel D Myers; Shirley K Wrobleski; K Barry Deatrick; Frank J Londy; John E Rectenwald; Peter K Henke; Robert G Schaub; Thomas W Wakefield Journal: Thromb Res Date: 2009-12-04 Impact factor: 3.944
Authors: Reyhan Diz-Kucukkaya; Murat Inanc; Vahid Afshar-Kharghan; Q Ed Zhang; José A López; Yuksel Pekcelen Journal: Ann Rheum Dis Date: 2007-06-01 Impact factor: 19.103
Authors: Daniel Myers; Patrick Lester; Reheman Adili; Angela Hawley; Laura Durham; Veronica Dunivant; Garrett Reynolds; Kiley Crego; Zoe Zimmerman; Suman Sood; Robert Sigler; William Fogler; John Magnani; Michael Holinstat; Thomas Wakefield Journal: J Vasc Surg Venous Lymphat Disord Date: 2020-03